Daily non-political popular news in brief.

PSA doubling predicts prostate cancer recurrence

A detectable level of prostate-specific antigen (PSA) is the first indicator of recurrent prostate cancer after radical prostatectomy. In a new Mayo Clinic study, the concept of PSA doubling time is found to be a reliable tool to distinguish which patients have prolonged innocuous PSA levels after therapy from those who are at great risk for disease recurrence and death from prostate cancer. Doubling time is defined as the duration for PSA levels in the blood to increase by 100 percent.

Read more »

Keywords: psa, doubling, predicts, prostate, cancer, recurrence, predict

« Previous | Next »

Similar news on "PSA doubling predicts prostate cancer recurrence":

1. Using additional biopsy-scoring data may help determine prostate cancer prognosis
   10-02-2007 · EurekAlert!
   Men with certain scores and patterns based on prostate cancer biopsy were found to be at higher risk of PSA-failure, suggesting that this measurement could help predict the risk of prostate cancer recurrence, according to preliminary research published in the Oct. 3 issue of JAMA.
   Similar news · Read more »
   
2. MR imaging helps predict recurrence in prostate cancer patients
   05-04-2007 · EurekAlert!
   MR images taken of prostate cancer patients prior to treatment that show that the cancer has spread outside the prostate gland capsule help predict whether the cancer will return, according to a recent study conducted by radiologists at the University of California-San Francisco.
   Similar news · Read more »
   
3. OHSU cancer institute researcher discovers new predictor of prostate cancer recurrence
   02-14-2008 · EurekAlert!
   An Oregon Health & Science University Cancer Institute researcher has found a biomarker that may help improve the ability to predict if a man's prostate cancer is going to come back after surgical removal.
   Similar news · Read more »
   
4. Study first: Over-expression of Cox-2 can predict prostate cancer outcome
   11-08-2006 · EurekAlert!
   Researchers say an over-expression of COX-2 in men with prostate cancer is associated with an increase in PSA after radiation treatment and the spread of the cancer outside of the prostate. That is the result of the first study linking COX-2 with prostate cancer radiation treatment outcomes.
   Similar news · Read more »
   
5. PSA testing can predict advanced prostate cancer
   02-14-2008 · EurekAlert!
   A single prostate specific antigen test taken before the age of 50 can be used to predict advanced prostate cancer in men up to 25 years in advance of a diagnosis, according to a new study published by researchers at Memorial Sloan-Kettering Cancer Center in New York and Lund University in Sweden.
   Similar news · Read more »
   
6. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
   06-02-2007 · EurekAlert!
   The study showed that sipuleucel-T did not significantly delay the time it took for a patient's PSA to reach a value of 3 ng/ml, the primary endpoint of the study, but it did show a prolongation in prostate-specific antigen doubling time (PSADT).
   Similar news · Read more »
   
7. Other highlights in the Dec. 11 JNCI
   12-11-2007 · EurekAlert!
   Also in the Dec. 11 JNCI are a drug that may reduce breast cancer recurrence, the risk of cancer after a blood transfusion, the association between PSA testing and prostate cancer diagnoses, and cancer risk among NBN mutation carriers.
   Similar news · Read more »
   
8. Early warning: PSA testing can predict advanced prostate cancer
   02-14-2008 · EurekAlert!
   Researchers find a single test taken before age 50 can aid prostate cancer diagnosis up to 25 years later.
   Similar news · Read more »
   
9. High pretreatment PSA velocity predicts worse outcome
   05-25-2007 · EurekAlert!
   The most significant single predictor of aggressive prostate cancer is an elevated rate of increase in prostate specific antigen (PSA) levels, according to a new study.
   Similar news · Read more »
   
10. PSA is poor predictor of lethal prostate cancer
    04-03-2007 · EurekAlert!
    The amount of prostate-specific antigen (PSA) in a man's bloodstream at the time of his prostate cancer diagnosis or its rate of change over the course of the disease does not adequately predict lethal prostate cancer, according to a study in the April 4 Journal of the National Cancer Institute.
    Similar news · Read more »